These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 34845)

  • 21. Case report of neuroleptic malignant syndrome associated with withdrawal from amantadine.
    Simpson DM; Davis GC
    Am J Psychiatry; 1984 Jun; 141(6):796-7. PubMed ID: 6145359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The risk of neuroleptic discontinuation in schizophrenia].
    Jarema M
    Psychiatr Pol; 1999; 33(1):69-81. PubMed ID: 10786216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis.
    Singh H; Hunt JI; Vitiello B; Simpson GM
    J Clin Psychiatry; 1990 Aug; 51(8):319-21. PubMed ID: 1974249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patients review: drug-induced movement disorders.
    Butković-Soldo S; Tomić S; Stimac D; Knezević L; Palić R; Jurić S; Marijanović K
    Coll Antropol; 2005 Dec; 29(2):579-82. PubMed ID: 16417164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Behavioral interactions induced by chronic neuroleptic therapy in persons with mental retardation.
    Schroeder SR; Gualtieri CT
    Psychopharmacol Bull; 1985; 21(2):310-5. PubMed ID: 2860695
    [No Abstract]   [Full Text] [Related]  

  • 26. Heroin use, diplopia, largactil.
    Iqbal N
    Saudi Med J; 2000 Dec; 21(12):1194. PubMed ID: 11360100
    [No Abstract]   [Full Text] [Related]  

  • 27. 'Withdrawal neuroleptic malignant syndrome': a phantom explanatory cause for a fatality.
    Gillman PK
    Med Sci Law; 2011 Apr; 51(2):122-3; author reply 124. PubMed ID: 21793478
    [No Abstract]   [Full Text] [Related]  

  • 28. Molindone and haloperidol in tardive dyskinesia.
    Glazer WM; Hafez HM; Benarroche CL
    J Clin Psychiatry; 1985 Aug; 46(8 Pt 2):4-7. PubMed ID: 2862139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cholinergic rebound in neuroleptic withdrawal syndromes.
    Lieberman J
    J Clin Psychiatry; 1981 Apr; 42(4):179. PubMed ID: 6110656
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical and epidemiologic aspects of tardive dyskinesia.
    Baldessarini RJ
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):8-13. PubMed ID: 2858483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The neuroleptic malignant syndrome].
    Duarte J; García Viejo MA; García Miguel FJ; Sempere AP
    Med Clin (Barc); 1994 Oct; 103(14):558. PubMed ID: 7799673
    [No Abstract]   [Full Text] [Related]  

  • 32. Dysphagia: a rare form of dyskinesia?
    Nieves JE; Stack KM; Harrison ME; Gorman JM
    J Psychiatr Pract; 2007 May; 13(3):199-201. PubMed ID: 17522565
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical and neurobiologic implications of antipsychotic-induced movement disorders.
    Rubin EH; Zorumski CF
    Compr Ther; 1986 Oct; 12(10):61-7. PubMed ID: 2877769
    [No Abstract]   [Full Text] [Related]  

  • 34. The rabbit syndrome.
    Decina P; Caracci G; Scapicchio PL
    Mov Disord; 1990; 5(3):263. PubMed ID: 1975087
    [No Abstract]   [Full Text] [Related]  

  • 35. Persistent tardive dyskinesia in randomly assigned neuroleptic reduction, neuroleptic nonreduction, and no-neuroleptic history groups: preliminary results.
    Kalachnik JE; Harder SR; Kidd-Nielsen P; Errickson E; Doebler M; Sprague RL
    Psychopharmacol Bull; 1984; 20(1):27-32. PubMed ID: 6144132
    [No Abstract]   [Full Text] [Related]  

  • 36. Neuroleptic malignant syndrome related to a switch to perospirone and anticholinergic withdrawal.
    Tanii H; Fujita K; Okazaki Y
    Am J Psychiatry; 2006 Mar; 163(3):547-8. PubMed ID: 16513884
    [No Abstract]   [Full Text] [Related]  

  • 37. [Acute recurrent dystonia secondary to neuroleptic suppression].
    Modrego Pardo P; Pérez Trullen JM
    Rev Clin Esp; 1997 Mar; 197(3):211-2. PubMed ID: 9273591
    [No Abstract]   [Full Text] [Related]  

  • 38. Management of tardive dyskinesia with thiopropazate.
    Curran JP
    Am J Psychiatry; 1973 Aug; 130(8):925-7. PubMed ID: 4146097
    [No Abstract]   [Full Text] [Related]  

  • 39. Cholinergic rebound in neuroleptic withdrawal syndromes.
    Lieberman J
    Psychosomatics; 1981 Mar; 22(3):253-4. PubMed ID: 6111828
    [No Abstract]   [Full Text] [Related]  

  • 40. New-onset extrapyramidal symptoms following oxcarbazepine discontinuation in a child receiving risperidone.
    Kruse JL; Davis MC
    J Child Adolesc Psychopharmacol; 2014 Apr; 24(3):166-7. PubMed ID: 24689943
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.